+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cholesterol Lowering Drug Market by Drug Class, Route of Administration, Molecule Type, Patient Age Group, Distribution Channel, Prescription Type - Global Forecast 2026-2032- Product Image
Cholesterol Lowering Drug Market by Drug Class, Route of Administration, Molecule Type, Patient Age Group, Distribution Channel, Prescription Type - Global Forecast 2026-2032- Product Image
Sale

Cholesterol Lowering Drug Market by Drug Class, Route of Administration, Molecule Type, Patient Age Group, Distribution Channel, Prescription Type - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011329
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cholesterol Lowering Drug Market is projected to reach USD 26.84 Billion in 2026. It is expected to continue growing at a CAGR of 5.71%, reaching USD 37.53 Billion by 2032.

The cholesterol lowering drug market is anchored by the clinical urgency of reducing low-density lipoprotein cholesterol, a causal and modifiable driver of atherosclerotic cardiovascular disease. The World Health Organization identifies cardiovascular disease as the leading global cause of death, while ACC/AHA and ESC/EAS guidelines continue to position LDL-C reduction as a core prevention strategy.

Demand is supported by large treated populations, broader lipid screening, aging demographics, diabetes and obesity prevalence, and therapy intensification for patients who do not reach guideline-recommended LDL-C thresholds with statins alone. Statins remain foundational, while ezetimibe, PCSK9 inhibitors, inclisiran, and bempedoic acid expand options for high-risk, familial hypercholesterolemia, and statin-intolerant patients.

Transformative Shifts in the Cholesterol Drug Landscape

The landscape is shifting from a statin-centered market toward a risk-stratified treatment model that combines low-cost generics with premium, outcome-oriented therapies. Evidence from major cardiovascular outcomes trials has strengthened confidence in intensive LDL-C reduction, especially for secondary prevention, very-high-risk ASCVD, and familial hypercholesterolemia.

Commercial dynamics are also changing as payers demand measurable value, physicians prioritize adherence-friendly regimens, and manufacturers refine access programs. Long-acting therapies, oral non-statin agents, and fixed-dose or sequential combination strategies are reshaping differentiation beyond efficacy to include dosing convenience, real-world persistence, affordability, and health-system integration.

Cumulative Impact of AI on Cholesterol Lowering Drugs

Artificial intelligence is increasingly cumulative across discovery, development, commercialization, and care delivery. In R&D, AI supports target identification, molecule screening, trial feasibility, patient stratification, and safety signal detection, helping teams shorten decision cycles while maintaining evidence standards and regulatory-grade documentation.

In market execution, AI-enabled analytics improve identification of undertreated high-risk patients, predict adherence gaps, and support personalized engagement for clinicians and payers. The strongest near-term impact is likely to come from integrating electronic health records, claims data, lipid panels, and guideline rules to close care gaps in ASCVD, diabetes-associated dyslipidemia, and familial hypercholesterolemia.

Key Regional Insights for Cholesterol Lowering Drugs

North America remains a high-value region due to advanced lipid testing, specialist adoption, Medicare and commercial payer coverage, and broad use of ACC/AHA guideline pathways. The United States anchors demand through intensive secondary prevention, cardiology-led prescribing, and specialty pharmacy infrastructure, while Canada emphasizes evidence-based reimbursement and population-level cardiovascular risk management. Europe benefits from ESC/EAS treatment targets, organized health systems, and strong secondary prevention programs, although national health technology assessment, formulary negotiation, and budget impact reviews influence the pace of premium therapy adoption across major European markets.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia confront rising cardiometabolic risk, aging populations, and broader access to diagnostics. Japan, South Korea, and Australia show high clinical sophistication and established screening, while China and India combine large untreated populations with expanding hospital networks and preventive care initiatives. Latin America shows demand linked to urbanization, diabetes prevalence, and greater physician awareness, with Brazil and Mexico leading regional scale opportunities. The Middle East is supported by a high cardiometabolic burden, particularly across GCC health systems, while Africa presents uneven access to lipid testing and medicines but growing public health attention to noncommunicable disease prevention.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

The G7 markets set the benchmark for clinical uptake, regulatory rigor, outcomes evidence, and reimbursement scrutiny, particularly for PCSK9 inhibitors, inclisiran, and bempedoic acid. The European Union emphasizes health technology assessment, budget impact, real-world evidence, and guideline alignment, supporting structured but country-specific access decisions. NATO countries broadly reflect mature cardiovascular care infrastructure across North America and Europe, although therapy access timelines vary based on national reimbursement rules, specialist prescribing criteria, and budget controls.

BRICS markets offer large patient pools, rising noncommunicable disease burden, and increasing domestic pharmaceutical capacity, with China and India central to volume-based treatment expansion and Brazil, Russia, and South Africa reflecting distinct access, procurement, and policy environments. ASEAN growth is driven by expanding lipid screening, private hospital networks, and public health attention to diabetes and cardiovascular disease, though affordability and reimbursement breadth remain critical. GCC countries show strong demand for premium cardiovascular care supported by high obesity, diabetes, and dyslipidemia prevalence, alongside public investment in preventive health, specialist services, and chronic disease management programs.

Key Country Insights for Major Cholesterol Lowering Drug Markets

The United States leads in therapeutic breadth, outcomes-driven prescribing, specialty drug commercialization, and use of ACC/AHA risk-based treatment pathways, while Canada emphasizes evidence-based reimbursement, lipid guideline adherence, and population-level cardiovascular prevention. Mexico and Brazil offer scale in Latin America as public and private systems address dyslipidemia alongside diabetes, hypertension, and obesity, with access shaped by insurance coverage, physician availability, and medicine affordability.

The United Kingdom, Germany, France, Italy, and Spain reflect mature guideline-based care, strong cardiology networks, and reimbursement pathways that shape premium therapy access through clinical eligibility, cost-effectiveness review, and formulary controls. Russia presents meaningful demand due to cardiovascular disease burden but greater policy, affordability, and supply-chain complexity. China and India combine large untreated or undertreated populations with expanding diagnostics, domestic manufacturing, and growing specialist capacity. Japan, Australia, and South Korea show high clinical sophistication, strong screening practices, aging-population demand, and increasing adoption of innovative lipid-lowering therapies for high-risk and statin-intolerant patients.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that connect LDL-C lowering to cardiovascular outcomes, adherence, safety, and total cost of care. Differentiation should move beyond efficacy claims to include real-world persistence, health equity, patient support, simplified treatment pathways, and practical integration into primary care, cardiology, endocrinology, and lipid clinic settings.

Manufacturers should invest in payer-aligned value communication, digital patient identification, and partnerships with laboratories, health systems, payers, and specialty pharmacies. Portfolio strategy should balance high-volume generics, combination products, oral non-statin options, and innovative therapies for high-risk populations where unmet need, guideline support, and willingness to reimburse are strongest.

Research Methodology for Cholesterol Lowering Drug Analysis

This executive summary is built on a triangulated research approach using publicly available clinical guidelines, regulatory information, peer-reviewed cardiovascular outcomes trial evidence, epidemiology from recognized public health organizations, and industry-level commercialization patterns. The analysis emphasizes verified relationships between LDL-C reduction, ASCVD risk management, treatment adherence, safety monitoring, and access dynamics.

Insights are synthesized through demand-side assessment, therapy-class evaluation, regional access review, policy analysis, and competitive trend mapping. No unverified market-size figures, market share estimates, or forecasts are used; instead, the methodology prioritizes defensible indicators such as disease burden, treatment guidelines, reimbursement structure, innovation adoption, affordability, and healthcare infrastructure maturity.

Conclusion: Outlook for Cholesterol Lowering Drugs

The cholesterol lowering drug market is evolving from broad statin use toward a layered treatment ecosystem that addresses residual cardiovascular risk, statin intolerance, familial hypercholesterolemia, and adherence barriers. Clinical evidence continues to validate LDL-C reduction as a central target in cardiovascular prevention, while guideline-directed therapy intensification is expanding the role of non-statin agents.

Future performance will depend on access, affordability, real-world adherence, and the ability to translate innovation into routine care. Organizations that combine strong outcomes evidence, AI-enabled patient identification, payer-ready value propositions, and region-specific access models will be best positioned to compete in this expanding therapeutic category.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cholesterol Lowering Drug Market, by Drug Class
7.1. Bile Acid Sequestrants
7.2. Cholesterol Absorption Inhibitors
7.3. PCSK9 Inhibitors
7.3.1. Alirocumab
7.3.2. Evolocumab
7.4. HMG-CoA Reductase Inhibitors (Statins)
7.4.1. Atorvastatin
7.4.2. Rosuvastatin
7.4.3. Simvastatin
8. Cholesterol Lowering Drug Market, by Route Of Administration
8.1. Injectable
8.2. Oral
9. Cholesterol Lowering Drug Market, by Molecule Type
9.1. Small Molecules Drugs
9.2. Monoclonal Antibodies
9.3. Nucleic Acid-based Drugs
10. Cholesterol Lowering Drug Market, by Patient Age Group
10.1. Adult
10.2. Pediatric
10.3. Senior
11. Cholesterol Lowering Drug Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Cholesterol Lowering Drug Market, by Prescription Type
12.1. Branded
12.2. Generic
13. Asia-Pacific Cholesterol Lowering Drug Market
14. Europe Cholesterol Lowering Drug Market
15. North America Cholesterol Lowering Drug Market
16. Latin America Cholesterol Lowering Drug Market
17. Africa Cholesterol Lowering Drug Market
18. Middle East Cholesterol Lowering Drug Market
19. NATO Cholesterol Lowering Drug Market
20. G7 Cholesterol Lowering Drug Market
21. BRICS Cholesterol Lowering Drug Market
22. European Union Cholesterol Lowering Drug Market
23. ASEAN Cholesterol Lowering Drug Market
24. GCC Cholesterol Lowering Drug Market
25. China Cholesterol Lowering Drug Market
26. United States Cholesterol Lowering Drug Market
27. Japan Cholesterol Lowering Drug Market
28. India Cholesterol Lowering Drug Market
29. Germany Cholesterol Lowering Drug Market
30. United Kingdom Cholesterol Lowering Drug Market
31. Australia Cholesterol Lowering Drug Market
32. France Cholesterol Lowering Drug Market
33. South Korea Cholesterol Lowering Drug Market
34. Italy Cholesterol Lowering Drug Market
35. Canada Cholesterol Lowering Drug Market
36. Russia Cholesterol Lowering Drug Market
37. Brazil Cholesterol Lowering Drug Market
38. Mexico Cholesterol Lowering Drug Market
39. Spain Cholesterol Lowering Drug Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. AbbVie Inc.
41.2. Alnylam Pharmaceuticals, Inc.
41.3. Amgen Inc.
41.4. Apotex Inc.
41.5. AstraZeneca PLC
41.6. Aurobindo Pharma Limited
41.7. Bayer AG
41.8. Boehringer Ingelheim International GmbH
41.9. Daiichi Sankyo Company, Limited
41.10. Dr. Reddy's Laboratories Limited
41.11. Eli Lilly and Company
41.12. Esperion Therapeutics, Inc.
41.13. Glenmark Pharmaceuticals Limited
41.14. Hetero Drugs Limited
41.15. Johnson & Johnson Services, Inc.
41.16. Kowa Company, Ltd.
41.17. Lupin Limited
41.18. Merck & Co., Inc.
41.19. Mylan N.V.
41.20. Novartis AG
41.21. Otsuka Holdings Co., Ltd.
41.22. Pfizer Inc.
41.23. Regeneron Pharmaceuticals, Inc.
41.24. Sandoz International GmbH
41.25. Sanofi S.A.
41.26. Shionogi & Co., Ltd.
41.27. Sun Pharmaceutical Industries Ltd.
41.28. Takeda Pharmaceutical Company Limited
41.29. Teva Pharmaceutical Industries Ltd.
41.30. Viatris Inc.
41.31. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BILE ACID SEQUESTRANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHOLESTEROL ABSORPTION INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHOLESTEROL ABSORPTION INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHOLESTEROL ABSORPTION INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PCSK9 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ALIROCUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ALIROCUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ALIROCUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL EVOLOCUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL EVOLOCUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL EVOLOCUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL HMG-COA REDUCTASE INHIBITORS (STATINS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL HMG-COA REDUCTASE INHIBITORS (STATINS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL HMG-COA REDUCTASE INHIBITORS (STATINS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ATORVASTATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ATORVASTATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ATORVASTATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ROSUVASTATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ROSUVASTATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ROSUVASTATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SIMVASTATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SIMVASTATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SIMVASTATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SMALL MOLECULES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SENIOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SENIOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SENIOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 92. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 93. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 95. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 96. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 116. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 118. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 119. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 120. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 122. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 134. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 136. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 137. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 138. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 140. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 141. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. NATO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 143. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 146. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 147. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 149. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 150. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. G7 CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 152. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 155. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 156. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 158. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 159. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. BRICS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 172. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 174. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 176. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. ASEAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 179. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 180. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 182. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 183. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 185. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 186. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. GCC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 188. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 189. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 191. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 192. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 194. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 195. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 206. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 207. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 208. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 210. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 212. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 213. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 215. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 218. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 219. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 221. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 222. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 224. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 228. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 230. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 231. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 242. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 243. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 246. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 248. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 249. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 250. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 251. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 253. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 254. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 255. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 257. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 258. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 259. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 260. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 261. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 262. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 263. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 264. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 265. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 266. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 267. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 268. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 269. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 270. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 271. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 272. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 273. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 275. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 276. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 277. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 278. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 279. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 280. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 281. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 282. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 283. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 284. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 285. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 286. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 287. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 288. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 290. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 291. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 292. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 293. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 294. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 295. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 296. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 297. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 298. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 299. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 300. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 301. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 302. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 303. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 305. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 306. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 307. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 308. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 309. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 310. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 311. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 312. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 313. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
TABLE 314. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 316. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 317. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS (STATINS), 2018-2032 (USD MILLION)
TABLE 318. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 319. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
TABLE 320. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 321. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 322. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Cholesterol Lowering Drug market report include:
  • AbbVie Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Johnson & Johnson Services, Inc.
  • Kowa Company, Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.84 Billion
Forecasted Market Value ( USD ) by 2032 $ 37.53 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2026-2034 - Product Image

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2026-2034

  • Report
  • 146 Pages
  • Global
From
Hyperlipidemia Drugs - Global Strategic Business Report - Product Image

Hyperlipidemia Drugs - Global Strategic Business Report

  • Report
  • 289 Pages
  • Global
From
Hypercholesterolemia Drug Market by Drug Class, Route of Administration, Disease Type, Age Group, Treatment Line, Distribution Channel - Global Forecast 2026-2032 - Product Image

Hypercholesterolemia Drug Market by Drug Class, Route of Administration, Disease Type, Age Group, Treatment Line, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Hyperlipidemia Drugs Market Size, Share, Trends and Forecast by Drug Type, End User, and Region, 2026-2034 - Product Image

Hyperlipidemia Drugs Market Size, Share, Trends and Forecast by Drug Type, End User, and Region, 2026-2034

  • Report
  • 135 Pages
  • Global
From
Atherosclerosis Drugs - Global Strategic Business Report - Product Image

Atherosclerosis Drugs - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From

About the Market

The Cholesterol Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat conditions related to the heart and circulatory system. Cholesterol Drugs are used to reduce levels of low-density lipoprotein (LDL) cholesterol, which is a major risk factor for cardiovascular disease. These drugs are typically prescribed to patients with high cholesterol levels, or to those at risk of developing cardiovascular disease. Common types of Cholesterol Drugs include statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. Some companies in the Cholesterol Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.